J&J jumps in­to gam­ma delta field with La­va col­lab­o­ra­tion; Myokar­dia guns for $605M raise

→ Jump­ing in­to the erupt­ing field of gam­ma delta T cells, J&J has signed a col­lab­o­ra­tion with La­va Ther­a­peu­tics. Like a se­ries of oth­er biotechs that have emerged in re­cent years, Nether­lands-based La­va de­vel­ops bis­pe­cif­ic an­ti­bod­ies that grab gam­ma delta T cells, which are in­volved in rec­og­niz­ing can­cers and oth­er types of anti­gens, to at­tack eva­sive tu­mors. Fi­nan­cial terms were not dis­closed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.